Cerity Partners LLC Purchases 900 Shares of Moderna, Inc. (NASDAQ:MRNA)

Cerity Partners LLC boosted its position in shares of Moderna, Inc. (NASDAQ:MRNA) by 7.0% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 13,769 shares of the company’s stock after purchasing an additional 900 shares during the period. Cerity Partners LLC’s holdings in Moderna were worth $920,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Ashton Thomas Private Wealth LLC purchased a new position in Moderna in the 2nd quarter worth about $26,000. Family Firm Inc. purchased a new position in shares of Moderna during the second quarter worth approximately $33,000. Hanseatic Management Services Inc. bought a new stake in shares of Moderna during the second quarter valued at approximately $48,000. Plato Investment Management Ltd boosted its holdings in shares of Moderna by 230.4% in the second quarter. Plato Investment Management Ltd now owns 413 shares of the company’s stock valued at $49,000 after purchasing an additional 288 shares during the period. Finally, Blue Trust Inc. lifted its holdings in shares of Moderna by 365.6% in the 3rd quarter. Blue Trust Inc. now owns 731 shares of the company’s stock worth $49,000 after buying an additional 574 shares during the period. 75.33% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

MRNA has been the topic of several research reports. Piper Sandler reissued an “overweight” rating and set a $69.00 price objective (down from $115.00) on shares of Moderna in a report on Monday, November 18th. Sanford C. Bernstein started coverage on Moderna in a report on Thursday, October 17th. They issued a “market perform” rating and a $55.00 price target on the stock. Oppenheimer cut Moderna from an “outperform” rating to a “market perform” rating in a research note on Friday, September 13th. Jefferies Financial Group cut their target price on Moderna from $65.00 to $55.00 and set a “hold” rating on the stock in a research note on Tuesday, October 15th. Finally, Barclays decreased their price target on shares of Moderna from $125.00 to $111.00 and set an “overweight” rating for the company in a research report on Friday, November 8th. Three equities research analysts have rated the stock with a sell rating, twelve have assigned a hold rating, five have given a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, the company has an average rating of “Hold” and a consensus target price of $83.33.

Insiders Place Their Bets

In other news, insider Shannon Thyme Klinger sold 1,418 shares of the stock in a transaction dated Friday, November 29th. The shares were sold at an average price of $42.79, for a total value of $60,676.22. Following the completion of the sale, the insider now directly owns 19,717 shares in the company, valued at $843,690.43. This represents a 6.71 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, CFO James M. Mock sold 715 shares of the company’s stock in a transaction dated Monday, October 7th. The shares were sold at an average price of $60.12, for a total transaction of $42,985.80. Following the sale, the chief financial officer now directly owns 9,505 shares of the company’s stock, valued at approximately $571,440.60. This represents a 7.00 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders sold 2,850 shares of company stock worth $134,560. Corporate insiders own 15.70% of the company’s stock.

Moderna Stock Up 3.1 %

MRNA opened at $42.94 on Friday. The company has a fifty day moving average of $50.69 and a two-hundred day moving average of $88.92. The stock has a market capitalization of $16.52 billion, a price-to-earnings ratio of -7.38 and a beta of 1.58. Moderna, Inc. has a fifty-two week low of $35.80 and a fifty-two week high of $170.47. The company has a debt-to-equity ratio of 0.05, a quick ratio of 4.20 and a current ratio of 4.39.

Moderna (NASDAQ:MRNA) last announced its earnings results on Thursday, November 7th. The company reported $0.03 earnings per share for the quarter, topping the consensus estimate of ($1.89) by $1.92. Moderna had a negative return on equity of 17.68% and a negative net margin of 43.77%. The business had revenue of $1.90 billion during the quarter, compared to the consensus estimate of $1.25 billion. During the same period in the prior year, the company posted ($1.39) EPS. The business’s quarterly revenue was up 3.8% on a year-over-year basis. On average, research analysts expect that Moderna, Inc. will post -9.32 earnings per share for the current year.

Moderna Company Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.